Thus, the serum thyroglobulin level is not an effective marker for the detection of recurrence and/or the therapeutic evaluation of long-term survival in PTC patients who have undergone surgery, in patients with a high titer of anti-thyroglobulin antibodies, or those whose tumor cells have transformed into undifferentiated carcinoma. This evidence concerns the gene TG and undifferentiated carcinoma.